A Phase III, Multi-centre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (OBERON)
PI(s): Laurie Snyder, Duke University; Chris Mosher, Duke University
Purpose: Purpose: This study seeks to test whether a biologic treatment reduces the rate of "acute exacerbation events" in patients with chronic obstructive pulmonary disease (COPD) who have a history of those worsening events ("acute exacerbations" are associated with decreased lung function, a decrease in health-related quality of life, and increased chance of death).
Study Design: Multi-CRN Interventional Study
PaTH Partners:
Coordinating Center: Duke University